Jeffrey Jackson is a notable inventor based in Schwenksville, PA (US). He has made significant contributions to the field of cancer treatment, particularly in the development of methods for treating LAG-3 positive tumors. With a total of 3 patents to his name, Jackson's work is paving the way for advancements in immunotherapy.

Latest Patents

One of Jeffrey Jackson's latest patents focuses on the treatment of LAG-3 positive tumors. The invention outlines a method for treating a tumor in a human patient, which includes identifying a patient as having a LAG-3 positive tumor and administering a PD-1 pathway inhibitor. This may involve a combination of a PD-1 pathway inhibitor and an immune checkpoint inhibitor, a combination of a LAG-3 inhibitor and a PD-1 pathway inhibitor, or an anti-CTLA4 antibody. The method can also include identifying the patient as having a LAG-3 positive PD-L1 positive tumor. In some cases, the LAG-3 inhibitor is an anti-LAG-3 antibody, while the PD-1 pathway inhibitor is an anti-PD-1 antibody. These methods aim to improve response rates to treatment with various inhibitors.

Career Highlights

Jeffrey Jackson is currently employed at Bristol-Myers Squibb Company, where he continues to innovate in the field of cancer research. His work has been instrumental in developing new therapeutic strategies that enhance patient outcomes.

Collaborations

Throughout his career, Jackson has collaborated with esteemed colleagues such as James Novotny, Jr. and Nils Lonberg. These partnerships have contributed to the advancement of his research and the successful development of his patents.

Conclusion

Jeffrey Jackson's contributions to cancer treatment through his innovative patents highlight the importance of research and collaboration in the medical field. His work continues to inspire advancements in immunotherapy and improve patient care.

This text is generated by artificial intelligence and may not be accurate.